Cargando…

Resistance to unfractionated heparin in the ICU: evaluation and management options

Detalles Bibliográficos
Autores principales:	Levy, Jerrold H., Frere, Corinne, Koster, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Understanding the Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242222/ https://www.ncbi.nlm.nih.gov/pubmed/37278759 http://dx.doi.org/10.1007/s00134-023-07103-x

Ejemplares similares

How to manage anticoagulation during extracorporeal membrane oxygenation
por: Levy, Jerrold H., et al.
Publicado: (2022)

Understanding resistance in Pseudomonas
por: Dimopoulos, George, et al.
Publicado: (2020)

Ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: understanding nebulization of aminoglycosides and colistin
por: Rouby, J. J., et al.
Publicado: (2020)

Bacterial and fungal superinfections in critically ill patients with COVID-19
por: Bassetti, Matteo, et al.
Publicado: (2020)

Targeting TMPRSS2 in SARS-CoV-2 Infection
por: Baughn, Linda B., et al.
Publicado: (2020)

Mechanical power: meaning, uses and limitations
por: Gattinoni, Luciano, et al.
Publicado: (2023)

Targeted immunomodulation: a primer for intensivists
por: Janssen, Malou, et al.
Publicado: (2023)

Understanding negative pressure pulmonary edema
por: Lemyze, Malcolm, et al.
Publicado: (2014)

From febrile pancytopenia to hemophagocytic lymphohistiocytosis-associated organ dysfunction
por: Carcillo, Joseph A., et al.
Publicado: (2017)

Understanding adrenal crisis
por: Amrein, Karin, et al.
Publicado: (2017)

Understanding renal recovery
por: Bell, Max, et al.
Publicado: (2017)

Understanding ethical decisions for patients on extracorporeal life support
por: Bein, Thomas, et al.
Publicado: (2017)

Paediatric Inflammatory Multisystem Syndrome Temporally-Associated with SARS-CoV-2 Infection: An Overview
por: Carter, Michael J., et al.
Publicado: (2020)

Ten tips to optimize weaning and extubation success in the critically ill
por: Jung, Boris, et al.
Publicado: (2020)

Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19
por: Joly, Bérangère S., et al.
Publicado: (2020)

Pulmonary immune responses against SARS-CoV-2 infection: harmful or not?
por: Guillon, A., et al.
Publicado: (2020)

Pulmonary complications in liver disease
por: Bauer, Michael, et al.
Publicado: (2019)

Climate change, global warming, and intensive care
por: Bein, Thomas, et al.
Publicado: (2019)

Ten diseases you need to know if you want to be a critical care specialist in Hong Kong
por: Joynt, Gavin M., et al.
Publicado: (2014)

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
por: Zhang, Haibo, et al.
Publicado: (2020)

Intra-cycle power: is the flow profile a neglected component of lung protection?
por: Marini, John J., et al.
Publicado: (2021)

Post-mortem dissection of COVID-19: a pathogenic role for macrophages?
por: Velu, Prasad P., et al.
Publicado: (2021)

Acute right ventricular injury phenotyping in ARDS
por: Zochios, Vasileios, et al.
Publicado: (2022)

Compartmentalisation of immune responses in critical illness: does it matter?
por: Conway Morris, Andrew, et al.
Publicado: (2022)

Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity
por: Mehta, Puja, et al.
Publicado: (2022)

Use of Mendelian randomization to better understand and treat sepsis
por: Russell, James A., et al.
Publicado: (2022)

Understanding base excess (BE): merits and pitfalls
por: Langer, Thomas, et al.
Publicado: (2022)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
por: Garcia, Flávio Luís, et al.
Publicado: (2015)

Nonclinical Evaluation of Novel Cationically Modified Polysaccharide Antidotes for Unfractionated Heparin
por: Kalaska, Bartlomiej, et al.
Publicado: (2015)

Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments
por: Davenport, Andrew
Publicado: (2012)

Impact of COVID-19 on monitoring of therapeutic unfractionated heparin
por: Adie, Sarah K., et al.
Publicado: (2020)

Quantitative Analysis of Impurities in Unfractionated Heparin of Bovine Origin
por: Workman, Wesley E., et al.
Publicado: (2020)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Impact of nebulized unfractionated heparin and N-acetylcysteine in management of smoke inhalation injury
por: Elamin, E, et al.
Publicado: (2009)

Unfractionated heparin in acute chest syndrome: a pilot feasibility randomized controlled trial of unfractionated heparin vs. standard of care in acute chest syndrome
por: Seaman, Craig D., et al.
Publicado: (2020)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory
por: Kim, Moo Hyun, et al.
Publicado: (2014)

Management of therapeutic unfractionated heparin in COVID‐19 patients: A retrospective cohort study
por: Weeks, Lachelle D., et al.
Publicado: (2021)

Magnetoencephalography
por: Proudfoot, Malcolm, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_643so13a1ob32gnms0s14k22jt